We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. The Administrator of personal data is STOCKTRADEIQ sp. z o.o., with its registered office in Poznan (61-625), at the following address: Czarna Rola 30 Street. Cookies policy here. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

  • Cookie
    cookieyes-consent
  • Duration
    1 year
  • Description
    CookieYes sets this cookie to remember users' consent preferences so that their preferences are respected on their subsequent visits to this site. It does not collect or store any personal information of the site visitors.
  • Cookie
    x-ms-cpim-csrf
  • Duration
    session
  • Description

    Inter-site request forgery token used to protect crSF. For more information, read the section Token falsification of requests between sites.

  • Cookie
    x-ms-cpim-sso:stocktradeiqauth.onmicrosoft.com_0
  • Duration
    session
  • Description

    Used to support single sign-on sessions. This cookie is set as persistent when the Keep me logged in option is enabled.

  • Cookie
    server-telemetry-{id}
  • Duration
    persistent
  • Description

    A value used by Microsoft for authorisation and authentication.

  • Cookie
    google_auto_fc_cmp_setting
  • Duration
    persistent
  • Description


    Stores the state of the User cookie for the current domain.

     

  • Cookie
    {id}-https://stocktradeiqauth.onmicrosoft.com/{id}
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    msal{id}.active-account
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-refreshtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-idtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    Microsoft Clarity
  • Duration
    1 year
  • Description

    Microsoft Clarity

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

  • Cookie
    isLightMode
  • Duration
    1 year
  • Description

    Defines the UI theme

  • Cookie
    userCultureData
  • Duration
    persistent
  • Description

     Stores information about the user's machine culture.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

  • Cookie
    _ga
  • Duration
    1 year 1 month 4 days
  • Description
    The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
  • Cookie
    _ga_*
  • Duration
    1 year 1 month 4 days
  • Description
    Google Analytics sets this cookie to store and count page views.
  • Cookie
    hotjar
  • Duration
    1 year 1 month 4 days
  • Description

    Analyzing users' behaviour in the website

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

  • Cookie
    __gpi
  • Duration
    1 year 24 days
  • Description
    Google Ads Service uses this cookie to collect information about from multiple websites for retargeting ads.
  • Cookie
    __gads
  • Duration
    1 year 24 days
  • Description

    The file, set by Google, is stored in the DoubleClick domain and tracks the number of times users view an ad, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain where it is set and does not track any data when browsing other sites.

  • Cookie
    goog:cached:topics
  • Duration
    persistent
  • Description

    It is used to record which adverts have been displayed to the User.

  • Cookie
    IDE
  • Duration
    year
  • Description

    Used by Google DoubleClick to record and report on the Website User's actions after viewing or clicking on an advertiser's ads in order to measure the effectiveness of the ad and present the User with targeted advertising.

  • Cookie
    google_experiment_mod44
  • Duration
    persistent
  • Description

    Used by Google Ad to experiment with the effectiveness of ads on websites using their services.

Powered by Cookieyes logo

    Get Diamond plan for FREE

    logo

    Tiziana Life Sciences Ltd (TLSA)

    Price:

    1.57 USD

    ( - -0.21 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    TLSA
    Name
    Tiziana Life Sciences Ltd
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    1.570
    Market Cap
    87.498M
    Enterprise value
    33.515M
    Currency
    USD
    Ceo
    Ivor R. Elrifi
    Full Time Employees
    9
    Website
    tizianalifesciences.com
    Ipo Date
    2018-11-20
    City
    London
    Address
    55 Park Lane

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    77.770B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    4.707B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    123.304B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -4.085
    P/S
    0
    P/B
    2.335
    Debt/Equity
    0.012
    EV/FCF
    5.757
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -0.245
    Debt/assets
    0.008
    FUNDAMENTALS
    Net debt/ebidta
    2.331
    Interest coverage
    -112.807
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.000
    Capex to revenue
    0
    Capex to depreciation
    0.033
    Return on tangible assets
    -0.370
    Debt to market cap
    Piotroski Score
    1.000
    FUNDAMENTALS
    PEG
    -0.229
    P/CF
    -10.967
    P/FCF
    -10.451
    RoA %
    -77.369
    RoIC %
    -41.198
    Gross Profit Margin %
    0
    Quick Ratio
    1.719
    Current Ratio
    1.719
    Net Profit Margin %
    0
    Net-Net
    0.422
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.083
    Revenue per share
    0
    Net income per share
    -0.191
    Operating cash flow per share
    -0.083
    Free cash flow per share
    -0.083
    Cash per share
    0.482
    Book value per share
    0.457
    Tangible book value per share
    0.457
    Shareholders equity per share
    0.335
    Interest debt per share
    0.006
    TECHNICAL
    52 weeks high
    2.600
    52 weeks low
    0.630
    Current trading session High
    1.810
    Current trading session Low
    1.295
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -10.804
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.016
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.436
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -11.704
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -8.570
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.150
    logo
    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -16.613
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.439
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -15.484
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.621
    DESCRIPTION

    Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

    NEWS
    https://images.financialmodelingprep.com/news/tiziana-life-sciences-announces-purchase-of-shares-by-chief-20251215.jpg
    Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

    globenewswire.com

    2025-12-15 15:07:00

    BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its Chief Executive Officer, Ivor Elrifi, has purchased 163,400 shares of Tiziana common stock in the open market. This brings his current purchased shares total to 357,848.

    https://images.financialmodelingprep.com/news/tiziana-ceo-boosts-stake-with-openmarket-share-purchase-20251215.jpeg
    Tiziana CEO boosts stake with open-market share purchase

    proactiveinvestors.com

    2025-12-15 10:21:00

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its Chief Executive Officer Ivor Elrifi has bought 163,400 shares of the biotechnology company’s common stock...

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-announces-withdrawal-of-proposed-public-offering-20251215.jpg
    Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

    globenewswire.com

    2025-12-15 07:30:00

    BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the withdrawal of the proposed public offering of common shares due to market conditions.

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-withdraws-proposed-share-offering-20251215.jpeg
    Tiziana Life Sciences withdraws proposed share offering

    proactiveinvestors.com

    2025-12-15 05:34:00

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) has withdrawn its proposed public offering of common shares, citing market conditions. The company, focused on...

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-to-begin-patient-dosing-in-phase-20251212.jpg
    Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer's trial next week

    proactiveinvestors.com

    2025-12-12 15:31:35

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial evaluating intranasal foralumab in early Alzheimer's disease, with the first patient expected to be dosed next week. The trial will study foralumab, a fully human anti-CD3 monoclonal antibody, as both a standalone therapy and in combination with the FDA-approved anti-amyloid drugs lecanemab or donanemab.

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-to-dose-first-patient-in-phase-20251212.jpg
    Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

    globenewswire.com

    2025-12-12 14:10:00

    BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer's clinical trial and plans to dose the first patient next week.

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-to-begin-patient-dosing-in-phase-20251212.jpeg
    Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer’s trial next week

    proactiveinvestors.com

    2025-12-12 10:27:00

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial...

    https://images.financialmodelingprep.com/news/vulcan-secures-22bn-to-fully-fund-phase-one-lionheart-20251203.jpeg
    Vulcan secures €2.2BN to fully fund Phase One Lionheart project

    proactiveinvestors.com

    2025-12-03 07:01:00

    Vulcan Energy Resources Ltd (ASX:VUL, OTC:VULNF, XETRA:VUL) has secured a €2.2 billion (about A$3.9 billion) financing package to fully fund Phase One of...

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-plans-spinout-of-il6-antibody-program-20251202.jpg
    Tiziana Life Sciences plans spinout of IL-6 antibody program

    proactiveinvestors.com

    2025-12-02 09:09:21

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed public company. Tiziana said its decision follows rising industry interest in the IL-6 pathway, highlighted by Novartis' $1.4 billion acquisition of Tourmaline Bio and its IL-6 inhibitor pacibekitug.

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-plans-to-spinout-il6-asset-into-20251202.jpg
    Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

    globenewswire.com

    2025-12-02 07:00:00

    BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501, and related assets (together “TZLS-501”) via a spinout into a separate publicly traded company, to enhance the strategic focus of each company and to drive value for shareholders.

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-plans-spinout-of-il6-antibody-program-20251202.jpeg
    Tiziana Life Sciences plans spinout of IL-6 antibody program

    proactiveinvestors.com

    2025-12-02 04:07:00

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into a separately listed...

    https://images.financialmodelingprep.com/news/nasdaq-dow-gain-with-dell-and-autodesk-boosting-tech-20251126.jpeg
    Nasdaq, Dow gain with Dell and Autodesk boosting tech

    proactiveinvestors.com

    2025-11-26 06:12:00

    11:10am: Jobless claims fall Initial US jobless claims fell by 6,000 to 216,000 for the week ending November 22, the lowest level since mid-April and well...

    https://images.financialmodelingprep.com/news/versarien-collapses-after-buyer-walks-away-leaving-company-weighing-20251126.jpeg
    Versarien collapses after buyer walks away, leaving company weighing administration

    proactiveinvestors.com

    2025-11-26 04:33:00

    Versarien PLC (AIM:VRS, OTC:VRSRF) shares sank 38% to 0.006p, valuing the troubled engineering materials group at about £330,000, after the company said a...

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-phase-2-foralumab-trial-joins-healey-20251125.jpg
    Tiziana Life Sciences' Phase 2 foralumab trial joins Healey ALS MyMatch Program

    proactiveinvestors.com

    2025-11-25 09:24:10

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted into the ALS MyMatch Program at the Sean M Healey & AMG Center for ALS at Mass General Brigham. The study, supported by a grant from the ALS Association, will be led by Principal Investigators Suma Babu and James Berry at Mass General Brigham.

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-nasal-foralumab-phase-2-clinical-trial-20251125.jpg
    Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

    globenewswire.com

    2025-11-25 08:30:00

    BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis (ALS) has been accepted for inclusion in the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham.

    https://images.financialmodelingprep.com/news/tiziana-life-sciences-phase-2-foralumab-trial-joins-healey-20251125.jpeg
    Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program

    proactiveinvestors.com

    2025-11-25 04:19:00

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral...